EUCTR2015-002631-17-ES进行中（未招募）1 期
An intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson?s disease (PD) patients
Institut de Recerca del Hospital de la Santa Creu i Sant Pau0 个研究点目标入组 18 人开始时间: 2015年11月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Male or female patients aged 40 to 80 years old with diagnosis of Idiopathic Parkinson?s Disease according to the London Brain Bank Criteria. [44]
- •2.Patients must be able and willing to provide informed consent to participate in the study.
- •3.Patients must be receiving optimized treatment with a stable dose of LCIG for at least four weeks before entering the study.
- •4.Patients must be experiencing motor fluctuations with a minimum of two hours/of OFF time during the awake day
- •5.Patients must have a Hoehn & Yahr stage between II and III in the ON condition [45].
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 9
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •1. Any form of parkinsonism other than idiopathic Parkinson?s disease.
- •2. Patients with deep brain stimulation or history of neurosurgical procedure.
- •3. Untreated depressive disorder.
- •4. Patients with functional illiteracy or impossibility to perform any of the tests (i.e. cognitive, blood test) of the study.
- •5. Severe or ongoing unstable medical conditions (e.g. cardiac, hepatic, pulmonary, renal, metabolic or endocrine).
- •6. Imminent risk of self-harm based on Investigator?s clinical judgment, with a ?yes? answer on item 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS)[50] at screening.
- •7. Parkinson?s Disease-Cognitive Rating Scale (PD-CRS) total score ? 64 and accomplishment of MDS criteria for dementia associated to PD at the time of screening [51, 52]. Patients with a PD-CRS total score ? 64, fulfilling diagnostic criteria for mild cognitive impairment in PD (PD-MCI) will be allowed to participate. [52, 53]
- •8. Patients with clinically significant apathetic symptoms as judged by both caregiver and neurologist and scoring > 14 on the Starkstein?s Apathy Evaluation Scale.[49]
- •9. Patients scoring ? 11 for anxiety and or depression on the Hospital Anxiety and Depression Scale (HADS). [37]
- •10. Previous history of any psychiatric condition as defined by the DSM-IV criteria based on the MINI International Neuropsychiatric Interview. [47, 54]
- •11. Patients with more than 30% of the day in off period and with dose failure episodes or unpredictable response to LD or severe dyskinesia that in opinion of the investigator could interfere with test performance or results.
- •12. Patients included in other clinical trial during the study period or 6 weeks before the study
- •13. Changes in psychotropic medication in the previous 4 weeks
- •14. Patients currently treated with: (i) Anticholinergic drugs; (ii) Typical neuroleptics, or any other drug which, in the opinion of the investigator, would interfere with the cognitive tests. Concomitant treatments with atypical neuroleptics (such as quetiapine, ziprasidone, or aripiprazole can be administered provided they remain at the lowest effective dose)
- •15. Permitted medications: anticholinesterase inhibitors and antidepressants initiated at least six weeks before study screening, or any other drug considered necessary for the safety and well-being of the patient are permitted during the study at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol in healthy subjects.healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardiaMedDRA version: 12.1Level: LLTClassification code 10040752Term: Sinus tachycardiaEUCTR2010-023311-34-CZAOP Orphan Pharmaceuticals AG
进行中（未招募）
不适用
A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, with an extended open-label inhaled corticosteroid period, in steroid-free, mild to moderate persistent asthma patientsEUCTR2008-005168-15-DEovartis Pharma Services AG50
已完成
2 期
Safety , Pharmacokinetics and efficacy of QAV680 in asthma patientsCTRI/2009/091/000282ovartis Healthcare Pvt Ltd50
已完成
不适用
A double-blind, randomised, double dummy, cross-over, study to assess the difference in efficacy between nebulisation of rhDNase in the morning versus nebulisation before going to sleepNutritional, Metabolic, EndocrineCystic fibrosisISRCTN74815264Roche Nederland BV (Netherlands)25
已完成
不适用
A randomized, double blind, two-way crossover clinical trial to evaluate of pharmacokinetic profiles of lacosamide in Korean subjectsKCT0003959Dong-A University Hospital48